awmsg logo



vandetanib (Caprelsa®)


Reference No. 3349

Publication date:
08/08/2017


Appraisal information

vandetanib (Caprelsa®) 100 mg film-coated tablet
vandetanib (Caprelsa®) 300 mg film-coated tablet


Company: Genzyme Therapeutics
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 07/08/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, vandetanib (Caprelsa®) cannot be endorsed for use within NHS Wales for the treatment of aggressive and symptomatic medullary thyroid cancer in children and adolescents aged 5 years to 18 years with unresectable locally advanced or metastatic disease.
Statement of Advice (SOA)
Download